Matinas BioPharma CEO Named Interim Chief Financial Officer

An update from Matinas BioPharma ( (MTNB) ) is now available.

On November 18, 2025, Matinas BioPharma Holdings, Inc. reported that its Chief Financial Officer, Keith Kucinski, would resign effective January 17, 2026, to pursue other opportunities, and on January 22, 2026, the board appointed Chairman, President and Chief Executive Officer Jerome D. Jabbour as interim Chief Financial Officer. Jabbour, a co-founder with extensive leadership and legal experience in healthcare and pharma, will simultaneously serve as the company’s principal financial and accounting officer without changes to his existing employment terms, and the company disclosed that his appointment involved no special arrangements, family relationships, or material related-party interests.

The most recent analyst rating on (MTNB) stock is a Hold with a $0.62 price target. To see the full list of analyst forecasts on Matinas BioPharma stock, see the MTNB Stock Forecast page.

Spark’s Take on MTNB Stock

According to Spark, TipRanks’ AI Analyst, MTNB is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, recurring losses, and continued cash burn) despite modest leverage. Technical indicators are mixed with only short-term stabilization and a broader downtrend, while valuation is difficult to support given negative earnings and no dividend.

To see Spark’s full report on MTNB stock, click here.

More about Matinas BioPharma

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company co-founded by Jerome D. Jabbour, who has held multiple leadership roles at the firm including President since 2016, Chief Executive Officer since 2018, and Chairman of the Board since March 2025, bringing prior experience from several healthcare, pharmaceutical and biotechnology organizations.

Average Trading Volume: 29,653

Technical Sentiment Signal: Sell

Current Market Cap: $4.08M

Learn more about MTNB stock on TipRanks’ Stock Analysis page.